

Determinazione del Responsabile Ufficio Formazione nº 881 del 2 0 AGO. 2015

Oggetto: Aggiornamento senza oneri, Dirigente Medico, Dott.ssa Sanna Daniela.

Pubblicata all'Albo Pretorio dell'Azienda Ospedaliera a partire dal 2 0 AGO 2015 per 15 giorni consecutivi e posta a disposizione per la consultazione.

#### Il Responsabile Ufficio Formazione

**Visto** 

il D. Lgs. n. 502/92 e successive modificazioni ed integrazioni:

**Viste** 

le Leggi Regionali n. 10/2006 e n. 05/2007;

Vista

la Deliberazione n. 263 del 04.03.2015, con la quale il Commissario Straordinario ha autorizzato il Responsabile dell'Ufficio Formazione Dott. Andrea Corrias, a predisporre le

Determinazioni;

Vista

la comunicazione Prot. n° 15330 del 30.07.2015 con la quale la Ditta Novartis Pharmaceuticals si è resa disponibile ad invitare un Medico della S.C. di Chirurgia Generale e Centro Trapianti di Fegato e Pancreas al "17th Congress of the European society for Organ Transplantation", che si terrà a Brussels dal 13.09.2015 al 16.09.2015:

Considerato

che il Direttore del Dipartimento di Chirurgia ha autorizzato a partecipare al suddetto Congresso la Dott.ssa Sanna Daniela:

Atteso

che il Responsabile dell'Ufficio Formazione ha espresso parere favorevole in merito;

Ritenuto

di dover autorizzare la partecipazione della Dott.ssa Sanna Daniela al "17th Congress of the European society for Organ Transplantation", che si terrà a Brussels dal 13.09.2015 al 16.09.2015; di dover prendere atto che le spese di partecipazione saranno totalmente a carico della Ditta Novartis Pharmaceuticals.

#### **DETERMINA**

Per i motivi esposti in premessa:

- Autorizzare la partecipazione della Dott.ssa Sanna Daniela al "17th Congress of the European society for Organ Transplantation", che si terrà a Brussels dal 13.09.2015 al 16.09.2015.
- 2. Dare atto che le spese di partecipazione saranno totalmente a carico della Ditta Novartis Pharmaceuticals.
- 3. Trasmettere la presente determinazione al Direttore della S.C. del Personale per gli adempimenti normativi di competenza.

Il Responsable dell'Ufficio Formazione

Dott Andrea Corrias

A

1 2 AGO, 7015





YOUR INTERNATIONAL PARTNER

PERVENUTO FOR CONGRESSES, EVENTS & COMMUNICATIO

Berlin | Brussels | Budapest | Florence | Lisbon | Madrid | Milan | Munich New York | Paris | Philadelphia | Prague | Rome | Sofia | Vienna

www.aimgroupinternational.com

Milano, 16 luglio 2015

C.A. COMMISSARIO STRAORDINARIO AZIENDA OSPEDALIERA BROTZE G. BROTZE CAGLIARI **DOTTORESSA PINTUS** 

PIAZZALE RICCHI, 1 09100 CAGLIARI

n 6 ASO. 2015

**ESOT** Brussels, 13 - 16 settembre 2015

Informiamo codesta Direzione che Novartis Pharmaceuticals inviterà un medico del Dipartimento Struttura semplice dipartimentale Trapianti dell'Azienda ospedaliera Brotzu al congresso in oggetto.

Novartis Pharmaceuticals si farà carico delle spese di iscrizione, viaggio e soggiorno relative alla persona indicata.

Grazie per l'attenzione e cordiali saluti.

**AO BROTZU** 

PG/2015/0015330

del 30/07/2015 ore 12,46

Mittente : AIM GROUP

Assegnatario : DIREZIONE GENERALE

AIM MEETING S.r.l. Via G.Ripamonti, 129 20141 Milano

Honere fourwish per le DANIECA SANARA

E TRAPIANTOUN Direttore: D

Øspedaliera "G. Brotzu"

TESSA DILCHARDITUTA GENERALE


TRO TRADIANTI DI FEGATO E PANCREAS

DIRETTORE: Dott. Fausto Zamboni

AIM Meeting Srl Milan Office Via G. Ripamonti 129 - 20141 Milan, Italy Tel +39 02 566011, Fax +39 02 56609055 info.aimmeeting@aimgroup.eu

Company with quality System Certified by SGS - ISO 9001:2008 | AIM Meeting S.r.l. - Reg. Imprese di Miland 00516790250 - Capitale sociale € 70.700 | Società a responsabilità limitata soggetta ad attività di direzione e coordinamento della AIM Group International SpA - Cod. Fisc. 05075630482







17th Congress of the European Society for Organ Transplantation

# FROM THE HEART OF EUROPE TO THE WORLD OF TRANSPLANTATION



13-16 September 2015 Brussels, Belgium

**Advanced Program** 

























The biennial congress of ESOT will take place in the capital of Europe – the theme for the meeting is 'From the Heart of Europe to the World of Transplantation'. ESOT 2015 will build on the recent very successful meetings in Vienna and Glasgow with all forms of modern educational and training alds in use. Besides different State of the Art sessions

dealing with several, still burning questions about organ donation and transplantation, many important European contributions in the field of organ and tissue transplantation as well as procurement will be highlighted. Attention will also be given to the European view in relation to ethical and legal aspects in the field of donation and transplantation.

## This is Brussels calling

Brussels is the thriving centre of Europe.

Brussels is home to the European Commission, Parliament and NATO, a buzzing, influential city where history is made. The city is a key European commercial hub too, a base for many progressive international companies. But more than that, Brussels is a compact city, friendly, positive, cosmopolitan, easy to get around. For a major European capital, Brussels is surprisingly eco-friendly too, peppered with parks and green spaces. A walk through Brussels takes you through a potted architectural history, from ancient medieval buildings to strikingly modern edifices, taking in the Art Nouveau styling of illustrious architect Victor Horta along the way.

We look forward to seeing you at a very fruitful and memorable congress in one capital or the European Union

Jan Letut and Dirk Van Raemdonck, Congress Chairs



## What we are planning

The Scientific Program Committee is made up of a blend of ESOT leaders, internationally established experts and young and talented transplant physicians, surgeons and scientists, all active in the various fields of transplantation. What are we planning for Brussels 2015? We want to set up a congress that reflects the "global" dimension that transplantation has acquired over the years. Indeed, today transplantation ranges from cells, to isolated organs, multi-organs and even composite tissue allograft transplantation. It is performed on all continents, requires the collaboration of a high number of distinct specialist areas, and is still the focus of burgeoning clinical and basic research. But there is more to it than that!

We are facing exciting times where the idea of organ transplantation is being expanded to a broader concept of functional organ replacement, in which new technologies are likely to play a prominent role in the very near future. Realization of ideas such as organ regeneration, bioengineering or 3D-printing may be around the corner. The ambition of this Congress is to present the highlights of transplantation today and what we think they might be tomorrow!

We will strive to capture this diversity in the development of the scientific program so that, whether young or old, scientist, surgeon or physician, whether looking for up-to-date knowledge on daily clinical practice or cutting edge research, every attendee can be sure to find a relevant and stimulating session.

We welcome your contributions and to sharing latest researches and clinical cases.

Daniel Abramowicz and Thierry Berney



- Enjoy a stimulating rejuvenated format with a focus on interaction and information exchange AMD the latest developments in the field of transplantation.
- Be inspired, educated, connected and entertained.
- Moving "Beyond the Harizon" with experts and innovative thinkers from all fields.
- A. Understand the latest trends in biomarkers, biologicals and immunosuppression and how this may change patient care.
- 5. Learn about the latest discoveries in the science of transplantation and aging.
- Experience translational research and recent developments at the interjunction between basic science and clinical care.
- Attend courses addressing the greatest surgical or immunological challenges.
- Discuss present and upcoming challenges in transplantation: where business, 8. legislation and medicine/science meet.
- Fresent your work and be selected as a case/topic for focused discussions guided and instructed by key opinion leaders in the field.
- 10. Get engaged in this interactive meeting and take an active role in shaping the future of transpiantation research and medicine.

## Table of content

2 > Scientific Program Overview

4 → Committees

5 → Specialty update Symposia

23 -> Registration fees

24 → ESOT 2015 Congress Awards

28 → Information

15 > Program

## Scientific Program Overview

	SPECIALTY SYMPOSIA
es.ee - 12.57 h	Pyreptrol  Parcoust & Betts by Elvin  Editor delice, epricipate and a societies of the soci
13.00 - · 16.30 h	See
76,45 - 75,75 k	Corporate Plenary Symposium
48.30 % 19.00 %	Opening & Plenary Session 1 ESOT meets the World
35.00 h	Brief Ordl Geisions Opening
19,00 ~ 72.00 h	Networking Event A Night at the Square

- 00-80 # 00-80	((000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(000)(	l Sessions		Brief Cral Session
09.10 + 36.40 h .	State of the Art 1 Global worming in transplantation	State of th B-Yond the humoral re in transpic	horizon: D Esponses la	tate of the Art 3 edgion tree or ittery: allocating rafts and therapi
10.86 ^ 11.10 h		Cálles	βτοαξί	
77.70 - 12.40 h	Full Oral Sessions	e version		Se Braile Mercel
53.00 - 14.00 h	Corporate Parallei Symposia	Future Li Forum by	eaders 🥌	Brief Orai Spesione
14,05 ~ 75,35 h	Plonary Session 2 Of mon and machine			
15.35 ~ 15.36 h		Coffee	N-ASh	
16.30 - 17.60 k	Beyondrie Port Person See Trestaturios See Pitrett Bally 2001		Full Oral Sessions	Bylef-Oral Sessions
17.00 - 18.90 h	SO SENIOS ESO	meets the ditors	seasions	OCORDIA
78.00 - 19.30 %	Corporate Plenary Symposium			

08.00 - 09.00 k	Full Oral Session	STEF Drut Sessions		
09.70 - 10.40 h	Then Mackers & makers trans	e of the Art 5 State of the Art 6 issue frontier: The enemy within splantation improving search compliance and cers. Trug levels	~****	
10.40 - 11.18 &	289	Stoc brook		
15.10 - 12.40 f;	Full Oral Sessions Strik Cuer Cuer	Manual The provide a second of		
75.90 - 76.00 h		ing Stays eo Session (PT Seksions		
36.85 ~ 15.25 a		ry Session 3 Intation 2.0.15		
15.35 * 15.08 h	Con	PARE DEPOSITS		
16.00 - 17.00 h	Sevend the occupant of Persons	SPECIAL SPECIA		
17.05 - 18.30 h	Full Oral Sessions	Corporate Planary Symposium	87.15 - 18,45 6	
18.30 - 15.30 h	NAMES OF THE OWNER OWNE	FDFAI 'Author Speed Signi' Duting' Cocktail	_	

•	
92.00 +	Full Oral Sessions Sirin Oral Session Session
09.70 - 34.40 <del>1</del>	State of the Art 7 State of the Art 9 State of the Art 9 Immunosuppression: Cell therapy: Life after streepipeline Hit or muss? transplantation: The pipeline transplantation: The pipeline Hit or muss? The pipeline Hit or muss?
10.40 - 11.10 h	Coffee break
15.70 - 33.00 r	Beyond the Horizon Presidential Session & Honorary Membership Ceremony
	CLOSING

#### Watershoot decirate

The target audience for this conference includes all fields involved in health care and research with an affiliation in transplantation. This includes but is not limited to:

- \* Transplant surgeons
- Physicians of all fields with an involvement in transplantation
- Coordinators, Nurses
- General surgeons and clinicians with an interest in transplantation
- Transplant scientists
- Nutrition and rehabilitation specialists and coordinators
- Transplant pharmacists

Further, health care professionals with an involvement in treatment of organ failure, cell therapy, tissue and regenerative medicine are warmly welcome to our conference.









## ESOT 2015 Brussels Congress Local Organizing Committee

#### Chairs:

Jan Lerut Dirk Van Raemdonck



#### Members:

Olivier Detry, Liège (ULG)
Vincent Donckier, Brussels (ULB)
Patrick Eurard, Mont-Godinne (UCL)
Jacques Pirenne, Leuven (KUL)
Xavier Roglers, Ghent (UG)
Bernard Stockman, Aalst (OLV)
Martin Wissing, Brussels (VUB)
Dirk Ysebaert, Antwerp (UA)



## Recal scientific blocket comunistes

#### Cincipa

Daniel Abramowicz, Antwerp, Belgium Thierry Berney, Geneva, Switzerland



#### Manthers:

Patrizia Burra, Padua, Italy | Franco Citterio, Rome, Italy | Edward Geissler, Munich, Germany | Denis Glotz, Paris, France | Maarten Naesens, Leuven, Belgium | Gabriel Oniscu, Edinburgh, United Kingdom | Andreas Pascher, Berlin, Germany | Luciano Potena, Bologna, Italy | Axel Rahmel, Frankfurt, Germany | Olivier Thaunat. Lyon, France | Teun van Gelder, Rotterdam, The Netherlands | Thomas Wekerle, Vienna, Austria

## ESOT 2015 Organizing Executive

Thierry Berney
Jan Lerut
Maarten Naesens
Gabriel Oniscu
Olivier Thaunat



## ESOT 2015 Sponsorship Advisory Committee



Thierry Berney, Geneva, Switzerland John Forsythe, Edinburgh, United Kingdom Stefan Schneeberger, Innsbruck, Austria Annalisa Ponchia, ESOT Executive Officer

### ESOT 2014 - 2015 Council

President: John Forsythe, Edinburgh, United Kingdom Past President: Carla Baan, Rotterdam, The Netherlands

Secretary: Thierry Berney, Geneva, Switzerland Treasurer: Stefan Schneeberger, Innsbruck, Austria



#### Councillors:

Marina Berenguer, Valencia, Spain | Diego Cantarovich, Nantes, France | Franco Citterio, Rome, Italy | Aksel Foss, Oslo, Norway | Robert Langer, Budapest, Hungary | Ugo Livi, Udine, Italy | Birgit Sawitzki, Berlin, Germany | Jonas Wadström, Stockholm, Sweden | Dirk Ysebaert, Antwerp, Belgium

### Members:

Lionel Badet, Lyon, France – VCA Committee Chair | D.L. Bensdorp – The Netherlands | Lisa Burnapp, London, United Kingdom – EDTCO Chair | Undine Gerlach, Berlin, Germany – YPT Committee Chair | Sir Peter Morris, London, United Kingdom – CET Director | Paolo Muiesan, Birmingham, United Kingdom – ELITA Chair | Rainer Oberbauer, Vienna, Austria – EKITA Chair | Vassilios Papalois, London, United Kingdom – Education Committee Chair | Rutger Ploeg, Oxford, United Kingdom – Ambassador Committee Chair | Luciano Potena, Bologna, Italy – ECTTA Chair | Johann Pratschke, Berlin, Germany – EPITA Chair | Willem Weimar, Rotterdam, The Netherlands – ELPAT Chair | Thomas Wekerle, Vienna, Austria – Basic Science Committee Chair

Executive Officer: Annalisa Ponchia, Padua, Italy





Sunday, September 13, 2015

### 09.00 - 12.50 → Specialty Update Symposium: Advances and challenges of Liver Transplantation for HCV liver cirrhosis

09.00 Introduction

Paolo Mulesan, Birmingham, United Kingdom

Christophe Duvoux, Paris, France

### Session 1: Liver Transplantation for patients with HCV Liver Cirrhosis

09:15 Liver transplantation for HCV liver cirrhosis in Europe -- results from the ELTR

René Adam, Paris, France

09.35 The new weapons and their combinations: the present and 5 year outlook

Thomas Berg, Leipzig, Germany

09.55 Expected epidemiologic changes in the liver transplant lists in Europe

Stefano Fagiuoli, Bergamo, Italy

10.20 - 10.40 Q&A

## Session 2: The new treatments for Hepatitis C in liver transplant candidates and recipients

11.10 New regimens in listed patients and ELITA recommendations

Luca S. Belli, Milan, Italy

11.30 New regimens for post transplant HCV disease recurrence and

ELITA recommendations

Christophe Duvoux, Paris, France

11.50 Cost effectiveness and sustainability of the new regimens

Sylvie Deuffic, Paris, France

12.10 The point of view of the patient

12.30 - 12.50 Q&A

**ELITA in pills:** The European Liver and Intestine Transplantation Association is a multi-disciplinary Society of health professionals in liver and intestine transplantation which is the official professional society delegated by ESOT for liver and intestine transplantation in Europe.

**Goals**: To provide a range of educational activities, stimulate discussion and influence European legislation in liver and intestine transplantation. In partnership with the European Liver Transplant Registry to stimulate clinical research and publications from analysis of the registry.

**Aim:** Our aim is to set guidelines and standards and to provide education and support in liver and intestine transplantation within the European Countries.

To provide the liver transplant professionals with up to date information on donor selection, anatomical and surgical technical pitfalls and management of recipients after small for size syndrome in split and living donor liver transplants.

Liver transplant surgeons and hepatologists, HPB surgeons and general hepatologists, HPB oncologists, specialist nurses in liver transplantation, HPB, hepatology and oncology.





Sunday, September 13, 2015

#### 09.00 – 12.50 → Specialty Update Symposium: Challenges in Pancreas and Islet Transplantation

#### Session 1: Unstable diabetes and treatment options

09.00 Pancreas transplantation?

Stephen Bartlett, Baltimore, United States

09,30

Islet transplantation?

Paul Johnson, Oxford, United Kingdom

00,00

We do not need either - we have insulin and technology

Pratik Choudhary, London, United Kingdom

10.30 - 10.40 Q&A

### Session 2: The future of beta cell therapy

11.10

The first clinical experience with islet scaffolds

Barbara Ludwig, Dresden, Germany

11.40

Stem cells are the future

Eelco de Koning, Leiden, The Netherlands

12.10

Islet encapsulation

Berit Lokengard Strand, Trondheim, Norway

12.40 - 12.50

Q&A


**EPITA in pills:** The European pancreas and Islet Transplantation Association is a section of ESOT founded to provide a Forum for the pancreas and islet transplantation community in Europe.

Goals: To facilitate the exchange of information of the field of pancreas and islet transplantation.

Aim: The aim of EPITA is to contribute to the development of the pancreas and islet transplantation field and of alternate forms of beta-cell replacement therapy for the benefit of patients suffering from type 1 diabetes.

Objectives: To review recent developments in pancreas and islet transplantation. To aim for an excellent graft survival despite increasing challenges in organ quality.

The pot anticodes: Transplant surgeons and physicians, transplant coordinator, nurses and medical student with an interest in transplantation of pancreas and islets.







## SPECIALTY UPDATE SYMPOSIA

Sunday, September 13, 2015

## 09.00 – 12.50 $\rightarrow$ EKITA-DESCARTES Joint Symposium: Personalization in Transplantation

09.00	Definition of sensitization (including solid phase technologies)

stratification and impact on the success of the Transplant

Søren Schwartz Sørensen, Copenhagen

09.20 Impact of sensitization on the waiting time – Simulations of real world data

Frans Claas, Leiden, The Netherlands

09.40 Cost-effectiveness of ABO-incompatible kidney transplantation and

kidney paired donation

Umberto Maggiore, Milan, Italy

10.00 Diagnosis and Treatment of ABMR based on the individual immunologic profile

Georg Böhmig, Vienna, Austria

10.20 ~ 10.30 Q&A

11.00 Novel tools/biomarkers to stratify diagnosis, prognosis and prediction

using omics technologies

Gunilla Einecke, Hannover, Germany

11.30 Pathophysiology and drug mechanism of action: systematic integration and

linking with outcome

Bernd Mayer, Vienna, Austria

12.00 - 12.50 Q&A to personalization in transplantation - live polls

Franco Citterio, Rome, Italy

**EKITA in pilis:** EKITA is the kidney section of ESOT and deals with all aspects of renal transplantation. As a European platform, EKITA supports research, education and clinical work in this area. Furthermore, EKITA is highly ambitious in preparing policies and creating transpational interactions to advance renal allografting in all European member states.


**Goals:** The main goal of EKITA is to improve quality of life of people with ESRD by advancing all aspects of kidney transplantation.

Aims: The ultimate aim of EKITA is the optimization of renal transplantation trough activities in research, education, clinical collaboration and health policy.

#### Descartes is an ERA-EDTA Working Group.

Objectives: To provide an overview and offer specific solutions for the 'complicated'/ sensitized patient. Solutions range from individualization through omics technologies to bioinformatics approaches.

Target audience: Transplant surgeons and physicians, nephrologist, immunologists at all stages of training and expertise.





Sunday, September 13, 2015

09.00 - 12.50 → Specialty Update Symposium:

Prevention, diagnosis and treatment of early and late thoracic graft dysfunction: a journey with the graft from the donor to the long-term recipient

## Session1: Thoracic organ donor management; setting the standards and pushing the limits

09.00 Report from the consensus conference on thoracic organ donors:

recommendations and unmet needs Arne Neyrinck, Leuven, Belgium

09.20 **Debate:** How to improve transportation and reconditioning of explanted lungs:

 Reconditioning while warm perfusion Dirk Van Raemdonck, Leuven, Belgium

→ Cold transportation and then bench reconditioning

Shaf Keshavjee, Toronto, Canada

10.00 How to optimize heart preservation and recovery

Bruno Podesser, Vienna, Austria

10.20 Resuscitating and transplanting a non-beating heart: "it-could-work!"

Macdonald Peter, Sydney, Australia

10.40 Featured abstract

Simon Messer, London, United Kingdom

## Session 2: Controversy and new knowledge in the management of machines and immunity

13.15 **Debate:** Optimize transplantation timing in VAD patients on the waiting list:

Only stable VAD patients should be transplanted

Andreas Zuckermann, Vienna, Austria

Only complicated VAD patients should be transplanted

Eugenij Potapov, Berlin, Germany

11.45 Modalities, indications and outcomes of patients needing ECMO support before

lung transplantation

Franco Valenza, Milan, Italy

12.05 Mechanisms of antibody mediated injury: looking for therapeutic targets in

thoracic transplantation

Elaine Reed, Los Angeles, United States

12.25 Featured abstract

Antoine Roux, Paris, France

12.40 Closing remarks

**ECTTA in pills:** The Thoracic Committee has been endorsed to promote initiatives aimed at improving the educational and scientific opportunities ESOT can offer to professionals involved in heart and lung transplantation.

**Goals:** Our ambition is to become a gathering home to foster scientific growth, exchange programs, collaborative projects and funding opportunities dedicated to European heart and lung transplantation programs.

Aim: Improve quality of care for patients with end-stage heart or lung disease and for thoracic organ transplant recipients. Advance education and stimulate networking amongst thoracic transplant professionals.

To provide updates on the etiologies, mechanisms, treatment strategies and diagnostic tools of early and late dysfunction of the transplanted heart and lungs. The lectures will focus on the main strategies and mechanisms leading to graft dysfunction starting from donor and organ management, to prevention of long-term chronic immunological injury leading to graft impairment.

Cardiologist, Pneumologists, Cardio-thoracic surgeons, Anestesiologists, Transplant coordinators.





Sunday, September 13, 2015

#### 09.00 - 12.50 → Specialty Update Symposium: VCA: Where are the limits, what is the future?

09.00 Limitations and results of face transplantation

Sylvie Testelin, Amiens, France

09.30 Limitations and results of upper limb transplantation

Stefan Schneeberger, Innsbruck, Austria

10.00 Laryngeal and Tracheal transplantation

Pierre Delaere, Leuven, Belgium

## 2<sup>rd</sup> Part: Joint Session Basic Science & Vascularized Composite Allotransplantation

11.10 Chronic rejection in VCA: from myth to reality

Olivier Thaunat, Lyon, France

11.40 Contributions of tissue engineering in VCA

Ramon Lull, Majorca, Spain

12.10 What have we learned from animal models in VCA?

Gerald Brandacher, Baltimore, United States

**VCA in pills:** VCA has opened a new era in the field of transplantation, reconstructive and restorative surgery. This committee brings together 10 representatives of major European teams at the forefront in this field.

**Goals:** Our goal is to raise the scientific and clinical development of Vascularized Composite Allotransplantation (VCA) in Europe and to serve as a platform for scientists and clinicians for information and exchange,

Objectives: Understand the risks and limits of face and upper limb transplantation; Discuss and implement new data to characterize chronic rejection; Discuss the contribution of animal models in VCA; Discuss alternatives strategies for patients management.

Target audience: Surgeons, physicians, researchers, transplant coordinators.



### 09.00 - 12.50 + BSC Specialty Update Symposium

09.00 Artificial organs/regenerative medicine

Harald Ott, Boston, United States

09.30 Rescuing organs (recovering and revitalizing discarded organs)

Henri Leuvenink, Groningen, The Netherlands

10.00 Xenotransplantation (of islets)

Massimo Trucco, Pittsburgh, Unites States

## 2nd Part: Joint Session Basic Science & Vascularized Composite Allotransplantation

11.10 Chronic rejection in VCA: from myth to reality

Olivier Thaunat, Lyon, France

11.40 Contributions of tissue engineering in VCA

Ramon Lull, Majorca, Spain

12.10 What have we learned from animal models in VCA?

Gerald Brandacher, Baltimore, United States

BSC in pills: The Basic Science Committee promotes Basic science in transplantation in Europe.

Goals: Translation of innovation into clinical activity; Communication between basic scientists and clinicians; Collaboration between laboratories in Europe.





## SPECIALTY UPDATE SYMPOSIA

Sunday, September 13, 2015

#### 08.30 – 12.50 → Healthcare Allied Professionals Joint Symposium ETAHP & ITNS Supporting self-management in transplant patients: an interdisciplinary journey

Session 1:	What should and could we do?
08.30	Introduction Marjo van Helden, Nijmegen, The Netherlands
08.40	Lifestyle problems: which issues do we face? Christiane Kugler, Hannover, Germany
09,10	Lifestyle interventions for transplant patients; state of the art Jasper Vanhoof, Leuven, Belgium
Session 2:	Promoting a healthy lifestyle: the roles of allied health disciplines
09.40	Role of the Advanced Practice Nurse Nathalie Duerinckx, Leuven, Belgium
10.00	Role of the physiotherapist Edwin van Adrichem, Groningen, The Netherlands
10.20	Role of the pharmacist Andrea Devaney, Oxford, United Kingdom
10.40	Role of the psychologist and social worker Inés Mega, Lisbon, Portugal
Session 3:	Tallored self-management interventions for vulnerable populations
11.20	People with low health literacy Cynthia Russell, Kansas City, United States
31.40	Adolescents and young adults Paul Harden, Oxford, United Kingdom
12.00	Elderly people Oliver Mauthner, Basel, Switzerland

**ETAHP In pills:** ETAHP reaches out to nurses, e.g. basic nurses, advanced practice nurses and nurse coordinators (recipient care); psychologists; physiotherapists; social workers; dieticians; pharmacists and other professionals working in the field of transplantation.

Goals: Within ETAHP, nurses and allied healthcare professionals throughout Europe will be united to ensure the best care possible to all transplant patients, with the aim to optimize patient outcomes.

Aims: We will do so by creating a strong European interdisciplinary platform to:

Panel discussion and take home messages Fabienne Dobbels, Leuven, Belgium

» share evidence -based knowledge

12.20 - 12.50

- exchange experiences and provide training
- $\rightarrow$  facilitate research and clinical collaborations
- $\Rightarrow$  set the standards for the quality of care in transplant nursing and for allied health professionals.

Objectives: The lectures will focus on post transplant lifestyle problems, the role of nurses and allied health professionals in promoting a healthy lifestyle, and non-medical interventions aiming to improve post-transplant self-management.

Target audience: Nurses, physical therapists, dieticians, social workers, occupational therapists psychologists, among other allied healthcare professionals.





Sunday, September 13, 2015

### 09.00 – 12.50 → Specialty Update Symposium: Living donor kidney exchange: Medical, Ethical, Legal, and Psychological Issues

09.00 Is it unethical for doctors to encourage healthy adults to donate a kidney to a stranger?

Antonia Cronin, London, United Kingdom

09.30 Unspecified donors and domino-paired chains

Willij Zuidema, Rotterdam, The Netherlands

10.00 Acceptability of public solicitation, the role of social media

Mihaela Frunza, Cluj, Romania

10.30 - 10.40 Q&A

11.10 The legal debate on anonymous donation

Leonie Lopp, Münster, Germany

11.40 Psychological outcomes after unspecified donation

Hannah Maple, London, United Kingdom

12.10 Ethical and practical issues of breaking anonymity

Linda Wright, Toronto, Canada

12.40 - 12.50 Q&A

**ELPAT in pills:** Ethical, Legal, and Psychosocial Aspects of organ Transplantation (ELPAT) is a European platform that brings continuity and progress in European research and dialogue on ethical, legal, and psychosocial aspects of organ donation and transplantation.

**Goals:** Provides a forum for discussion about ethical, legal, and psychosocial problems and questions related to donation and transplantation; Organizes regular, international open and invitational conferences.

Objectives: To increase the knowledge, understanding, and skills to implement a successful living kidney exchange program.

Target audience: Nephrologists, surgeons, psychologists, social workers, transplant coordinators, nurse practitioners.







Sunday, September 13, 2015

## 09.00 – 16.00 $\Rightarrow$ EDTCO 2015 Symposium Brussels: Donation at the end-of-life; routine rather than exception

Session 1:	Donation at the end of life; what do we do well and what could we do better?
09.00	Lessons learned from ACCORD Beatriz Dominguez-Gil, Madrid, Spain & Paul Murphy, Leeds, United Kingdom
09.20	Engaging intensive care professionals in deceased donation: What can the transplant community do?  Axel Rahmel, Frankfurt, Germany
09.35	What can professional societies do? Daniel de Backer, European Society of Intensive Care Medicine, Brussels, Belgium
09.50	What can individuals do? Stephan Eschertzhuber, Innsbruck, Austria
10.05 - 10.25	Audience and speakers discussion
Session 2:	Family approach: theory into practice
	Family approach: the way I do it when
10.40	Brain death criteria are met Paolo Maia, Porto, Portugal
10.55	Brain death is expected, but has not occurred yet Teresa Pont, Barcelona, Spain
11.10	Circulatory death is expected to occur following the Withdrawal of Life Sustaining Treatment (Controlled DCD) Tineke Wind, Maastricht, The Netherlands
11.25	Unexpected circulatory death occurs following unsuccessful cardiopulmonary resuscitation (Uncontrolled DCD)  Anna Faucher, Annecy, France
11.40 - 12.00	Audience and speakers discussion
Session 3;	The Moral Maze: Upholding the overall best interests of the dying patient CHAIRS: Lisa Burnapp, London, United Kingdom Dirk Ysebaert, Antwerp, Belgium
13.00	Is it ethically and legally defensible to overrule the expressed consent of the dying patient to be an organ donor?  • For: Michael Bos, The Hague, The Netherlands  • Against: David Shaw, Glasgow, United Kingdom
13.20 - 13,35	Audience and speakers discussion
13.35	Is ethically and legally defensible to initiate and continue active treatment beyond futility to incorporate the option of organ donation in the end-of-life care pathway?  • For: Dale Gardiner, Nottingham, United Kingdom • Against: Julien Charpentier, Paris, France
13.55 ~ 14.10	Audlence and speakers discussion

Benstenn 2 --- -

## SPECIALTY UPDATE SYMPOSIA

Sunday, September 13, 2015

Session 4;	How can we raise awareness and engage society and the public in the deceased organ donation debate?
14.25	Advertising for donation after death: what makes a difference? Jeantine Reiger, Leiden, The Netherlands
14.50	Social media: do the benefits outweigh the risks in engaging the public?
14.50	Patient perspective Nicholas Palmer, Head of Advocacy at the National Kidney Federation
15.00	Donor family perspective
15.10	Healthcare professional perspective Danica Avsec, Ljubljana, Slovenia
15,20	Journalist perspective
15.30 - 16.00	Audience and panel discussion

EDTCO in pills: EDTCO is a section within ESOT dedicated to donation and procurement activities.

**Goals:** Increase organ and tissue availability; Ensure the quality and safety of organs and tissues for transplantation; Optimise the safety of living donors and care for deceased donors and their relatives; Optimise potential recipient care and follow-up through effective clinical coordination.

**Aim:** To establish clinically effective programmes in organ and tissue donation, procurement and transplantation by supporting and representing all healthcare professionals involved in the process.

Objectives: To promote better understanding of the barriers to deceased donation;
To develop knowledge and skills in end of life care, donor management and family support;
To enhance collaboration between healthcare professionals working in the fields of intensive care medicine and organ and tissue donation.

Target audience: Healthcare professionals involved in intensive care and emergency medicine, end of life care, organ and tissue donation and coordination. Patient, family and society representatives, EU commissioners and political representatives.





falk to me and I will forget.

Teach me and I might remember.

Involve me and I will learn!!!

- Benjamin Franklin

09.00

Welcome and introduction

Vassilios Papalois, Education Committee Chair

09.10

Presentation of the Campfire format and themes Frank Dor, Education Committee Vice-Chair

09.20 - 09.35

Thoms 1: European Transplant Feliowship and Mentorship Programs.

The time has come to learn from each other

Introduced by Bynvant Sandhu, London, United Kingdom

this is where we will discuss:

New avenues in transplant education, training and professional development.

Transplant programs across Europe.

09.35 ~ 09.50

Theme 2: Keep Calm, you are not alone with your decision:

The MDT is here to help

Introduced by Herold Metselaar, Rotterdam, The Netherlands

This is where we will discuss:

Decision making when part of a multidisciplinary transplant team.

09.50 - 10.20

Thems 3: Tools to deal with the information Tsunami. How to become an

Information Master

Introduced by Simon Knight, Oxford, United Kingdom

& Luca Toti, Rome, Italy

This is where we will discuss:

How to master the tsunami of medical information.

Quality lifelong learning.

10.20 - 10.35

Thems &: The DO's and DON'Ts of starting and growing a new

transplant program

Introduced by Andrew Ready, Birmingham, United Kingdom

This is where us will discuss:

\* The Aim and the Motivation.

The Best Approach for a deep-rooted and long lasting program.

10.35 - 13.30

Light the fire!

Group discussion over presented themes

11.30 - 12.15

Get together

Reports from groups

12.15 - 12.50


Summary of the outcomes from the campfire and take home actions

Vassilios Papalois, Education Committee Chair Frank Dor, Education Committee Vice-Chair


Who should attend: Any Transplant Professional from Senior to Generation Y

The Education Committee is dedicated to:

- 7 Promoting the overall educational philosophy and programs of ESOT
- Organising and supporting the advanced courses which are part of the formal ESOT education pathway
- Collaborating with the ECs of Transplant Societies across Europe and beyond to promote transplant education in a mutually beneficial way
- Provide quality control for the UEMS-ESOT Exams in Transplantation, Surgery, Medicine, Coordination and Immunology



ESOT 2015 PROGRAM



ESOT Brussels 2015

## **SUNDAY, 13 SEPTEMBER**





16.30 - 18.30 OPENING of the ESOT 2015 Brussels Congress

16.30 - 16.45 Welcome addresses by the Congress Chairs:

Jan Lerut, Brussels, Belgium; Dirk van Raemdonck, Leuven, Belgium

16.45 - 18.00 ESOT Meets the World

Moderator: John Forsythe, ESOT President

KEY LEARNING:

Overview of transplantation in culturally diverse regions

Forum on major issues on Transplantation, discussants:

For the American Society of Transplantation: Dan Salomon, San Diego, United States For the Asian Society of Transplantation: Chao-Long Chen, Taipei, Taiwan

For the Middle East Society of Transplantation:

Seyed Ali Malek-Hosseini, Shiraz, Iran

For the South Latin American & Caribbean Society of Transplantation:

Valter Duro García, Porto Alegre, Brasil

Who should attend: General, Donation policies, Politics, Cultural issues

18.00 - 18.25 PIANO PERFORMANCE by Enrica Ciccarelli

18.25 - 18.45 Keynote presentation: Building a more Social Europe, One Step at a Time

Herman van Rompuy, President European Council emeritus

19.00 - 21.00 'Speed Dating' Poster Session Opening &

Networking evening: A night at the Square

## MONDAY, 14 SEPTEMBER

09.10 - 10.40 STATE OF THE ART 1 → Global warming in transplantation

### KEYLEARNING Increasing the organ pool quality and quantity 07.60 Cool is beautiful Philipp Dutkowski, Zurich, Switzerland

09,30 Can we escape global warming? Gabriel Oniscu, Edinburgh, United Kingdom

09.50 Keeping the heart warm and the lungs breathing Martin Strueber, Grand Rapids, United States

10.10 The down on the new ice age

Korkut Uygun, Boston, United States

10.30 Q&A

Who should attend: Surgeons, Scientists, Coordinators

### ...MONDAY, 14 SEPTEMBER



09.10 - 10.40	STATE OF THE ART 2 → B-yond the horizon: humoral responses in transplantation
09.10	Humoral responses: basic concepts in cinemascope! Facundo Batista, London, United Kingdom
06.60	Detection and clinical relevance of donor specific antibodies Frans Claas, Leiden, The Netherlands
09.50	Antibody-independent functions of B cells in allograft rejection Geetha Chalasani, Pittsburgh, United States
10.10	B cells not always the bad guys: B cell regulatory functions Sophie Brouard, Nantes, France
10.30	Q&A
09.10 - 10.40	STATE OF THE ART 3 $\rightarrow$ Decision tree or lettery: allocating grafts and therapies
00.00	Tailor made organ allocation  Axel Rahmel, Frankfurt, Germany
09.30	Tallor made surgery Peter Friend, Oxford, United Kingdom
09.50	Tailor made immunosuppression Teun van Gelder, Rotterdam, The Netherlands
10,10	Tailor made post transplant follow up? Bryce Kiberd, Halifax, Canada
10.30	Q&A
11.10 - 12.40	"The Devil's Advocate" Contradictory discussion of clinical trials
11,10	Case 1. Defender: Aksel Foss, Oslo, Norway Is Liver Transplantation an Option in Colorectal Cancer Patients with Nonresectable Liver Metastases and Progression on All Lines of Standard Chemotherapy? Ann Surg Oncol. 2014 Oct 9. [Epub ahead of print]. Dueland S, Hagness M, Line PD, Guren TK, Tveit KM. Foss A.
	Case 1. Defender: Aksel Foss, Oslo, Norway Is Liver Transplantation an Option in Colorectal Cancer Patients with Nonresectable Liver Metastases and Progression on All Lines of Standard Chemotherapy? Ann Surg Oncol. 2014 Oct 9. [Epub ahead of print]. Dueland S, Hagness M, Line PD, Guren TK, Tveit KM, Foss A. Opponent: François Pruvot, Lille, France
11.10 11.20	Case 1. Defender: Aksel Foss, Oslo, Norway Is Liver Transplantation an Option in Colorectal Cancer Patients with Nonresectable Liver Metastases and Progression on All Lines of Standard Chemotherapy? Ann Surg Oncol. 2014 Oct 9. [Epub ahead of print]. Dueland S, Hagness M, Line PD, Guren TK, Tveit KM, Foss A. Opponent: François Pruvot, Lille, France Discussion  Case 2. Defender: Arne Andreassen, Oslo, Norway Everolimus initiation and early calcineurin inhibitor withdrawal in heart transplant recipients: a randomized trial. Am J Transplant. 2014 Aug. Andreassen AK, Andersson B, Gustafsson F, Eiskjaer H, Radegran G, Gude E, Jansson, K, Solbu D, Sigurdardottir V, Arora S
11.10 11.20 11.30	Case 1. Defender: Aksel Foss, Oslo, Norway Is Liver Transplantation an Option in Colorectal Cancer Patients with Nonresectable Liver Metastases and Progression on All Lines of Standard Chemotherapy? Ann Surg Oncol. 2014 Oct 9. [Epub ahead of print]. Dueland S, Hagness M, Line PD, Guren TK, Tveit KM, Foss A. Opponent: François Pruvot, Lille, France Discussion  Case 2. Defender: Arne Andreassen, Oslo, Norway Everolimus initiation and early calcineurin inhibitor withdrawal in heart transplant recipients: a randomized trial. Am J Transplant. 2014 Aug. Andreassen AK, Andersson B. Gustafsson F.
11.10 11.20 11.30 11.40	Case 1. Defender: Aksel Foss, Oslo, Norway Is Liver Transplantation an Option in Colorectal Cancer Patients with Nonresectable Liver Metastases and Progression on All Lines of Standard Chemotherapy? Ann Surg Oncol. 2014 Oct 9. [Epub ahead of print]. Dueland S, Hagness M, Line PD, Guren TK, Tveit KM, Foss A. Opponent: François Pruvot, Lille, France  Discussion  Case 2. Defender: Arne Andreassen, Oslo, Norway Everolimus initiation and early calcineurin inhibitor withdrawal in heart transplant recipients: a randomized trial. Am J Transplant. 2014 Aug. Andreassen AK, Andersson B, Gustafsson F, Eiskjaer H, Radegran G, Gude E, Jansson, K, Solbu D, Sigurdardottir V, Arora S, Deligren G, Gullestad L.
11.10 11.20 11.30 11.40	Case 1. Defender: Aksel Foss, Oslo, Norway Is Liver Transplantation an Option in Colorectal Cancer Patients with Nonresectable Liver Metastases and Progression on All Lines of Standard Chemotherapy? Ann Surg Oncol. 2014 Oct 9. [Epub ahead of print]. Dueland S, Hagness M, Line PD, Guren TK, Tveit KM, Foss A. Opponent: François Pruvot, Lille, France  Discussion  Case 2. Defender: Arne Andreassen, Oslo, Norway Everolimus initiation and early calcineurin inhibitor withdrawal in heart transplant recipients: a randomized trial. Am J Transplant. 2014 Aug. Andreassen AK, Andersson B, Gustafsson F, Eiskjaer H, Radegran G, Gude E, Jansson, K, Solbu D, Sigurdardottir V, Arora S, Deligren G, Gullestad L. Opponent: Luciano Potena, Bologna, Italy  Discussion  Case 3. Defender: Anit Garg, London (Ontario), Canada Gestational hypertension and preeclampsia in living kidney donors. N Engl J Med. 2015 Jan 8; Garg AX, Nevis IF, McArthur E, Sontrop JM, Koval JJ, Lam NN, Hildebrand AM, Reese PP, Storsley L, Gill JS, Segey DI, Habbous S
11.10 11.20 11.30 11.40 11.50 12.00	Case 1. Defender: Aksel Foss, Oslo, Norway Is Liver Transplantation an Option in Colorectal Cancer Patients with Nonresectable Liver Metastases and Progression on All Lines of Standard Chemotherapy? Ann Surg Oncol. 2014 Oct 9. [Epub ahead of print]. Dueland S, Hagness M, Line PD, Guren TK, Tveit KM, Foss A. Opponent: François Pruvot, Lille, France  Discussion  Case 2. Defender: Arne Andreassen, Oslo, Norway Everolimus initiation and early calcineurin inhibitor withdrawal in heart transplant recipients: a randomized trial. Am J Transplant. 2014 Aug. Andreassen AK, Andersson B, Gustafsson F, Eiskjaer H, Radegran G, Gude E, Jansson, K, Solbu D, Sigurdardottir V, Arora S, Deligren G, Gullestad L. Opponent: Luciano Potena, Bologna, Italy  Discussion  Case 3. Defender: Anit Garg, London (Ontario), Canada Gestational hypertension and preeclampsia in living kidney donors. N Engl J Med. 2015 Jan 8; Garg AX, Nevis IF, McArthur E, Sontrop, IM, Koyal J. J. Figure 1. J. Med. 2015 Jan 8; Garg AX, Nevis IF, McArthur E, Sontrop, IM, Koyal J. J. Figure 2. Defender: Anit Garg AX, Nevis IF, McArthur E, Sontrop, IM, Koyal J. J. Figure 2. Defender: Anit Garg AX, Nevis IF, McArthur E, Sontrop, IM, Koyal J. J. Figure 2. Defender: Anit Garg AX, Nevis IF, McArthur E, Sontrop, IM, Koyal J. J. Figure 2. Defender: Anit Garg AX, Nevis IF, McArthur E, Sontrop, IM, Koyal J. J. Figure 2. Defender: Anit Garg AX, Nevis IF, McArthur E, Sontrop, IM, Koyal J. J. Figure 2. Defender: Anit Garg AX, Nevis IF, McArthur E, Sontrop, IM, Koyal J. J. Figure 2. Defender: Anit Garg AX, Nevis IF, McArthur E, Sontrop, IM, Koyal J. J. Figure 2. Defender: Anit Garg AX, Nevis IF, McArthur E, Sontrop, IM, Koyal J. J. Figure 2. Defender: Anit Garg AX, Nevis IF, McArthur E, Sontrop, IM, Koyal J. J. Figure 2. Defender: Anit Garg AX, Nevis IF, McArthur E, Sontrop, IM, Koyal J. J. Figure 2. Defender: Anit Garg AX, Nevis IF, McArthur E, Sontrop, IM, Koyal J. J. Figure 2. Defender: Anit Garg AX, Nevis IF, McArthur E, Sontrop, IM, Koyal J. J. Figure 2. Defender: Anit Garg

### ...MONDAY, 14 SEPTEMBER



13.00 - 14.00

Future Leaders Forum by Young Professional in Transplantation Committee Forum with representatives from:



ASTS Vanguard Group: Mike Englesbe, Ann Arbor, United States BTS – British Transplantation Society: Bynvant Sandhu, London, United Kingdom ESOT: Antje Habicht, Munich, Germany ILTS Vanguard Group: Burcin Ekser, Indianapolis, United States

→ Who should attend: younger physicians, surgeons and scientists who have an interest in transplantation

14.05 - 15.35	PLENARY SESSION 2: Of men and machine
14.05	Printing the human body John D. Jackson, Winston-Salem, United States
14.20	Artificial organs: a step towards the bionic man? Shuvo Roy, San Francisco, United States
14.40	The ethics of the Robot Liam Plant, Cork, Ireland
15.00	Keynote presentation II: I, Cyborg! Kevin Warwick, Coventry, United Kingdom
	→ Who should attend: General interest, artificial organs
15.00 - 17.00	"BEYOND THE HORIZOM" & The future of the human body
16.00	Giving Birth to Uterus Transplantation Mats Brännström, Gothenburg, Sweden
16.20	Neural stem cells for spinal cord repair – Ready to walk the talk? Norbert Weidner, Heidelberg, Germany
16.40	Changing the face of transplantation Stephen Bartlett, Baltimore, United States
	→ Who should attend: General interest, no specialization required
16.90 - 17.00	"BETOND THE HORIZON" 2: The race of tolerance with regenerative medicine
16.00	The Odyssey of tolerance induction in solid organ transplantation Herman Waldmann, Oxford, United Kingdom
16.20	The promises of regenerative medicine Harold Ott, Boston, United States
16.40	Racing against or complementing each other? Sam Strober, Palo Alto, United States

## ...MONDAY, 14 SEPTEMBER



17.00 <b>– 18.00</b>	ESOT meets the Editors Round table and interactive session with questions from the floor to discuss issues related to medical journal publication:  o Impact factor: how is it calculated? o Reviewing process o Submitters' choice and common mistakes  Editors' from major medical journals present and answer questions from the audience;
	<ul> <li>American Journal of Transplantation (AJT): Sandy Feng and John O'Grady,</li> <li>Senior Editors</li> <li>Transplant International (TI): Thomas Wekerle, Editor-in-Chief</li> </ul>
	- Transplantation Direct: Edward Geissler, Executive Editor
17.00 - 18.00	HOTT Project Workshop - Organ trafficking anno 2015: the latest insights
17,00	Revealing the modus operandi of organ trafficking networks Martin Gunnarson, Lund, Sweden
17.20	Tackling organ trafficking: a prosecutor's perspective Jonathan Ratel, Pristina, Kosovo
17.40	Transplant professionals should breach their secrecy oath Frederike Ambagtsheer, Rotterdam, The Netherlands

## **TUESDAY, 15 SEPTEMBER**

09.10 - 10.40	STATE OF THE ART 4 $\Rightarrow$ Markers and makers of success and failure	
09.10	Personalized medicine and precision medicine in solid organ transplantation Dan Salomon, San Diego, United States	
09.30	Drinking from the fire hose – a critical appraisal of biomarkers in transplantation Rainer Oberbauer, Vienna, Austria	1
09.50	Facing the hurdles to clinical implementation of novel biomarkers Hans-Dieter Volk, Berlin, Germany	
10,10	Biomarker implementation in clinical practice: the regulatory agency's perspecting Thorsten Vetter, EMA London, United Kingdom	υe
10.30	Q&A	
	→ Who should attend: Physicians and Translational Researchers	
09.10 - 10.40	STATE OF THE ART 5 → The new frontier: transplantation across antibody barriers	
09.10	Squaring the circle: Hybridizing desensitization with paired exchange Bob Montgomery, Baltimore, United States	
09.30	Acceptable mismatches, past and future Ilias Doxiadis, Leiden, The Netherlands	
09.50	ABO incompatible liver transplantation Gi-Won Song, Seoul, Korea	
10.10	Autoantibodies against the graft, do they mean anything? Dany Anglicheau, Paris, France	
10.30	Q&A	

### ...TUESDAY, 15 SEPTEMBER



09.10 - 10.40	STATE OF THE ART 6 → The enemy within: improving compliance and drug levels			
00.00	Intra-patient variability of drug concentrations as a predictor of non-adherence Dirk Kuypers, Leuven, Belgium			
09.30	Risk factors of poor adherence, prevention and education in adult Giacomo Germani, Padua, Italy			
09.50	New tools to detect non-adherence Sabina de Geest, Basel, Switzerland			
10.10	The journey from adolescence to adulthood Paul Harden, Oxford, United Kingdom			
10.30	Q&A			
11.10 - 12.40	"The Devil's Advocate" Contradictory discussion of Basic Science Studies			
11.10	Case 1. Defender: Olivier Hermine, Paris, France G-CSF mobilizes CD34+ regulatory monocytes that inhibit graft-versus-host disease Maud D'Aveni, Julien Rossignol, Tereza Coman, Shivajanani Sivakumaran, Stephen Henderson, Teresa Manzo, Pedro Santos e Sousa, Julie Bruneau, Guillemette Fouquet, Flora Zavala, Olinda Alegria-Prévot, Meriem Garfa- Traoré, Felipe Suarez, Hélène Trebeden-Nègre, Mohamad Mohty, Clare L.			
11.20	Bennett, Ronjon Chakraverty, Olivier Hermine, and Marie-Thérèse Rubio Opponent: James Hutchinson, Regensburg, Germany			
11.30	Discussion			
11.40	Case 2. Defender: Fadi Lakkis, Pittsburgh, United States Non-self recognition by monocytes initiates allograft rejection Martin H. Oberbarnscheidt, Qiang Zeng, Qi Li, Hehua Dai, Amanda L. Williams, Warren D. Shlomchik, David M. Rothstein, and Fadi G. Lakkis			
11.50	Opponent: Herman Waldmann, Oxford, United Kingdom			
12.00	Discussion			
12.10	Case 3. Defender: Guillaume Canaud, Paris, France Inhibition of the mTORC Pathway in the Antiphospholipid Syndrome Guillaume Canaud, Frank Bienaimé, Fanny Tabarin, Guillaume Bataillon, Danielle Seilhean, Laure-Hélène Noël, Marie-Agnès Dragon-Durey, Renaud Snanoudj, Gérard Friedlander, Lise Halbwachs-Mecarelli, Christophe Lagander, and Fabilla Tari			
12.20	Christophe Legendre, and Fabiola Terzi Opponent: Alexandre Hertig, Paris, France			
12.30	Discussion			
	Guess what? Striking clinical cases by Education Committee Interactive and very instructive session where difficult cases and difficult decisions will be addressed as in a quiz. Win confidence and solve the problem.			

13.00 - 14.00



Rising Stars Video Session by YPT

New methods not always become 'public', we are going to look for hidden rising stars to make them visible! This session is reserved for innovative projects or methodology that will be presented in a video.

#### ...TUESDAY, 15 SEPTEMBER



14.05 - 15.35	PLENARY SESSION 3: Transplantation 2.0.15					
14.05	Social Media and transplantation: an ethical point of view Adam Peña, Houston, United States					
14.25	Age of real-time medicine Bart Van Den Bosch, Leuven, Belgium					
14.45	Will Big Data reshape transplantation? Dorry Segev, Baltimore, United States					
15.05	<u>Keynote presentation III: Reshaping healthcare through eHealth</u> Lucien Engelen, Nijmegen, The Netherlands					
	→ Who should attend: General interest, no specialization required					
16.00 - 17.00	"BEYOND THE HORIZON" 3: Organ resuscitation lab					
	Reconditioning the organs versus growing the organs					
16.00	Organ reconditioning: the new transplant evolution? Jacques Pirenne, Leuven, Belgium					
16.20	From scaffolds to functioning organs Doris Taylor, Houston, United States					
16,40	The organ hub – the future model for solid organ transplantation Shaf Keshavjee, Toronto, Canada					
	→ Who should attend: Physicians and Translational Researchers					
16.00 - 12.00	The first that first the first the first the first that the first the first the first the first that the first the f					
	"BEYOND THE HORIZON" 4: Crazy transplants or transplants of tomorro					
16.00	Vascularized organ xenotransplantation Robin Pierson, Baltimore, United States					
16.20	Growing new organs in vivo Hiro Nakauchi, San Francisco, United States					

## WEDNESDAY, 16 SEPTEMBER

09.10 - 10.40 STATE OF THE ART 7 → Immunosuppression: Is the pipeline empty?

	the property;
KEY LEARNING:	→ How to get new drugs in our field
09.10	Promising novel agents: what happened to them? Klemens Budde, Berlin, Germany
09,30	What are the new immunosuppressive drugs in the pipeline? Christophe Legendre, Paris, France
09.50	New immunosuppressants: interaction between academia, biopharma and regulatory agencies Randall Morris, Palo Alto, United States

## ...WEDNESDAY, 16 SEPTEMBER



10,10	Drug repositioning: teaching old drugs new tricks Yves Moreau, Leuven, Belgium			
10,30	Q&A			
	→ Who should attend: General interest, Physicians			
09.10 - 10.40	STATE OF THE ART 8 → Cell therapy: Hit or miss?			
09.10	Mesenchymal Stem Cells in Organ Transplantation Carla Baan, Rotterdam, The Netherlands			
09.30	Application of suppressive antigen presenting cells in transplantation James Hutchinson, Regensburg, Germany			
09.50	The present status and future of regulatory T cell therapy in organ transplantation Robert Lechler, London, United Kingdom			
10.10	Cell therapy for diabetes Camillo Ricordi, Miami, United States			
10.30	Q&A			
09.10 - 10.40	STATE OF THE ART 9 -> Life after transplantation: blessing or curse?			
01.60	Long-term organ transplant recipient survivors: quality of life Christiane Kugler, Hannover, Germany			
09.30	Sexual function and fertility after solid organ transplant Patrizia Burra, Padua, Italy			
09.50	Pregnancy after solid organ transplant Corinne Hubinont, Brussels, Belgium			
10.10	Physical activity and sports in organ transplant recipients Alessandro Nanni Costa, Rome, Italy			
10.30	Q&A			
11.00 – 13.00	PLENARY SESSION 4: Beyond the Horizon Presidential & Honorary Membership			
11.00	Keynote presentation IV: Beyond the Horizon: the astronaut's view Jean-Francois Clervoy, ESA astronaut			
11.20	Beyond the horizon in clinical science Maarten Naesens, Leuven, Belgium			
11.40	Beyond the horizon in basic science Menna Clatworthy, Cambridge, United Kingdom			
12.00	Presidential address			
12.15	Honorary member SG LEE, Seoul, Korea Introduced by Jan Lerut, Brussels, Belgium			
12.35	Honorary member Gerald Opelz, Heldelberg, Germany			
12.55 – 13.00	Closing remarks			

## ESOT 2015 Congress Registration Fees

Type of registration	<b>Early registration</b> by 31 May 2015	<b>Late registration</b> by 30 August 2015	<b>On site</b> by 12 September 2015
	N. C. (2016)	K-960	(47)10
	1.57.27.00 p. 1.57.00		
	£ 350	EAID	C-440
		e dese	4.496

Fees are inclusive of VAT at the prevailing rate.

Delogate registration fee includes:


- Admission to the all scientific sessions
- Admission to all Specialty Update Symposia
- → Access to the exhibition
- \* Access to delegate lounges
- → Participant's kit with congress material
- Provision of the required device for use throughout the duration of the congress
- Admission to poster opening & networking reception
- → Refreshment breaks

## **Ecosystem**

ESOT 2015 will be a paperless congress, printed matters will be fully replaced by a multifeature App, to maximize participants engagement and connectivity.









## **ESOT 2015 Congress Awards**



As part of the ESOT commitment to advancing education and research in Transplantation, the following Awards will be assigned to abstract presenters in recognition of their contribution.

All Awardees will be required to be ESOT members.

### BAC - Best Abstract Challenge supported by



10 outstanding contributions, selected by the ESOT 2015 Scientific Program Committee from all submitted abstracts based on the overall referees' score, will be presented during the BAC Session on Monday 14th September, from 11.10 to 12.40 h.

The Audience will vote to select 6 finalists, 3 clinical and 3 basic science works, to which these awards will be assigned to.



#### YIA - Young Investigator Awards supported by



10 awards will be assigned to young clinicians or scientists (under 40 years of age in 2015), who have submitted abstracts to the ESOT 2015 Brussels Congress.

Awards are assigned by the Scientific Program Committee of the ESOT 2015 Congress and announced at the congress.



# EUROLIVER FOUNDATION Awards Euroliver



The EUROLIVER Foundation was set up in 1992 by the late Mr Herman TOB and Prof Jean-Bernard OTTE of the University Hospital St-Luc in Brussels. Belgium in order to support research projects in the field of liver transplantation and organ donation, and also to improve the psychosocial support of both future liver recipients and liver transplant patients.

2 awards are assigned to young researchers who have made a valuable contribution in relation to these topics.

Awards are assigned by the ELITA Board and announced at the congress.





BELDONOR is an initiative of the federal public services from the Belgian Ministry of Health supporting the development of organ donation.

5 awards are assigned to Five professionals and they will be awarded for best research presented in the field of Allocation and Donation.



#### EDITA Amerca



Two prizes will be awarded to distinguish the best abstracts presented in the field of Islet and Pancreas transplantation respectively.

Awards are assigned by the EPITA Board and announced at the congress.



## ECTTA Awards



For the first time at ESOT Congress, ECTTA has instituted 4 awards for the following topics:

1. Improvement of thoracic organ procurement (including donor management, organ reconditioning, DCD donors) One Oral presentation will be awarded with € 1.000 and two Posters will be awarded with € 500 each



2. Diagnosis and management of antibody mediated rejection in heart or lung transplant recipients One Oral presentation will be awarded with € 1.000



A Thermo Eisher Scientific Brand

2 Oral Awards amount to € 1000 each



Awards will be assigned to submitted abstract selected by the ECTTA Board and announced at the congress. Candidates must be under 40 years of age at the moment of submission. The Awardees of the Oral presentations will be invited to present their abstracts during the ECTTA Specialty Update Symposium, on Sunday 13th September from 09.00 to 12.50 h.

### BO - Best Oral Presentation Award



The award for the Best Oral Presentation will be assigned to the Oral Presentation most 'voted' by the attendees during the Congress. The audience can express more than one preference via the Congress App, where all presentations will be available.



## BBO – Best Brief Oral Presentation Award .....



The award for the Best Brief Oral Presentation will be assigned to the Brief Oral Presentation most 'voted' by the attendees during the Congress. The audience can express more than one preference via the Congress App, where all presentations will be available.



## **ESOT Corporate Partners**
















## **ESOT 2015 CONGRESS SUPPORTERS**


ESOT wishes to acknowledge the support of the following partners, who have already confirmed their participation:

PLATINIUM





GC LE



















#### 多红沙医器





#### BRONZE












#### **EXHIBITORS**



















## znoitazinadao tigoag-kok
















## information

#### ABOUT TARGET AUDIENCE



The target audience for the meeting includes all professionals involved in clinical care and research related to organ and cellular transplantation as well as organ and tissue donation.

Beside transplant researchers, physicians and surgeons, all different allied health professionals involved in transplantation and donation such as pharmacists, nurses, psychologists, nutrition and rehabilitation specialists, clinical and donation coordinators are warmly welcome.

The meeting is also addressed to health care professionals involved in the expanding fields of care of organ failure and regenerative medicine.

## **ABOUT THE VENUE**





The SQUARE meeting Centre: an architectural landmark in its own right, in the vibrant Mont des Arts cultural quarter in the heart of Brussels. It sits easily among the city's major museums and art galleries, including the recently opened Magritte Museum, devoted to the country's aster of surrealism.

All the major shops and tourist attractions are just a short stroll away, and there are plenty of good hotels to choose from in the neighborhood. SQUARE is situated in front of the Central Station, handy for the international airport and train connections.

#### HOTEL ACCOMMODATION




A number of rooms in different hotel categories has been blocked at preferential rates. Several hotels are located close to the venue at walking distance or within easy reach with public transport system. The full list of hotels is available on the website http://esot2015.esot.org

Make sure to book your room and benefit from the preferential rates.

LATE REGISTRATION DEADLINE:

я B August 2015

ESOT Brussels 2015



Visit: esot.org

Contants & information

ESOT 2015 Brussels Congress Secretariat ESOT Office Corso del Popolo, 8 - 35131 Padua, Italy Phone +39 049 8597652 Egy +39 049 2106307

Fax +39 049 2106307 esot2015@esot.org

### Congress Administrative Secretariat

AIM Group International Phone +43 1 402 77 55 - 613 esot2015@aimgroup.eu

## Rapp invio fax

## 13-AGO-2015 12:33 GIO

Numero fax

070539752

Nome

UFF. FORMAZIONE

Nome/Numero

00256609055

Pag.

Ora iniz.

13-AGO-2015 12:32 GIO

Tempo trascorso:

00'34" STD G3

Modalita'

Risultati

[O.K]

UPFICIO FORMAZIONE

1 2 AGO, 2015 PERVENUTO

YOUR INTERNATIONAL PARTNER FOR CONGRESSES, EVENTS & COMMUNICATION

Bedin | Brussels | Budapest | Forence | Lisbon | Madrid | Milan | Munich New York | Paris | Philadelphia | Prague | Rome | Sofia | Vienna

www.aimgroupinternational.com

Milano, 16 luglio 2015

C.A. COMMISSARIO STRAORDINARIO AZIENDA OSPEDALIERA BRATOSE -G. BROTEIT - CAGLIARI DIPARTIMENTO DI CHEURGIA E TRABBILITO DI CHEURGIA PIAZZALE RICCHI, 1 09100 CAGLIARI

0 6 AGO, 2015

ESOT

Brussels, 13 - 16 settembre 2015

Informiamo codesta Direzione che Novartis Pharmaceuticals inviterà un medico del Dipartimento Struttura semplice dipartimentale Trapianti dell'Azienda ospedaliera Brotzu al congresso in oggetto.

Novartis Pharmaceuticals si farà carico delle spese di iscrizione, viaggio e soggiorno relative alla persona indicata.

Grazie per l'attenzione e cordiali saluti.

AO BROTZU

PG/2015/0015330 del 30/07/2015 ore 12,46

Mittente : AIM CROUP

AIM MEETING S.r.l. Via G.Ripamonti, 129 20141 Milano

AIM Meeting Srl

Milan Office Via G. Ripamonti 129 - 20141 Milan, Italy Tel +39 02 566011, Fax +39 02 56609055 Info.aimmeeting@aimgroup.eu

E TRAPIA Direttore: D DALIERA "G. BROTZU"

AZIENDA OSPEDATE C A GLU DIPARTIMENVO

CAGLIA FI MUNICIPA DILLUMBRITIA GENERALE TRABIANTOT FEGATO E PANCREAS

DIRETTORE Buit Fausto Zamboni

Company with quality System Cortified by SCS ISO 9001:2008 | AlM Meeting S.r.l. - Reg. Impress of Miland 00516790250 - Capitale sociale € 70.700 | Sociatà a responsabilità limitata soggetta ad attività di direzionalm Group International SpA - Cod. Fisc. 05075630487